To determine the impact of ATCV-1 on MND we used a mouse model in which SOD1-G93A-transgenic mice develop ALS-like MND around 150 days of age and progress to severe morbidity and mortality by day 170. Here, SOD1 is linked to mild neurocognitive disorder.